# A Window of Opportunity Trial of Mirdametinib Plus Vorinostat for NF1 Associated, H3K27 Trimethylation Deficient Malignant Peripheral Nerve Sheath Tumor [MPNST]

> **NCT06693284** · EARLY_PHASE1 · RECRUITING · sponsor: **University of Minnesota** · enrollment: 8 (estimated)

## Conditions studied

- Primary Malignant Peripheral Nerve Sheath Tumors

## Interventions

- **DRUG:** mirdametinib and vorinostat

## Key facts

- **NCT ID:** NCT06693284
- **Lead sponsor:** University of Minnesota
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-11-20
- **Primary completion:** 2027-01-01
- **Final completion:** 2027-01-01
- **Target enrollment:** 8 (ESTIMATED)
- **Last updated:** 2026-02-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06693284

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06693284, "A Window of Opportunity Trial of Mirdametinib Plus Vorinostat for NF1 Associated, H3K27 Trimethylation Deficient Malignant Peripheral Nerve Sheath Tumor [MPNST]". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06693284. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*